LAVA Therapeutics NVNASDAQ:LVTX
- LAST PRICE1.6500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.6200/ 27
- Ask / Lots1.7200/ 11
- Open / Previous Close--- / 1.6500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LVTX |
|---|---|---|
| 09:38 ET | 1001 | 1.65 |
| 09:52 ET | 6190 | 1.65 |
| 10:14 ET | 3000 | 1.6201 |
| 10:15 ET | 3000 | 1.622 |
| 10:17 ET | 14915 | 1.6205 |
| 10:19 ET | 8386 | 1.6627 |
| 11:04 ET | 6484 | 1.685 |
| 11:13 ET | 100 | 1.6667 |
| 11:18 ET | 4500 | 1.63 |
| 11:20 ET | 100 | 1.6299 |
| 11:31 ET | 385 | 1.61 |
| 11:33 ET | 893 | 1.61 |
| 11:42 ET | 2000 | 1.63 |
| 11:49 ET | 1418 | 1.63 |
| 11:54 ET | 1218 | 1.645 |
| 12:27 ET | 1997 | 1.62 |
| 12:43 ET | 300 | 1.6299 |
| 12:50 ET | 100 | 1.6259 |
| 12:56 ET | 200 | 1.625 |
| 01:14 ET | 2267 | 1.6 |
| 01:15 ET | 433 | 1.6 |
| 01:17 ET | 1900 | 1.5982 |
| 01:21 ET | 100 | 1.6 |
| 01:44 ET | 100 | 1.6 |
| 01:46 ET | 600 | 1.6075 |
| 02:00 ET | 1361 | 1.61 |
| 02:11 ET | 122 | 1.63 |
| 02:51 ET | 200 | 1.6 |
| 03:16 ET | 100 | 1.62 |
| 03:21 ET | 5000 | 1.6798 |
| 03:23 ET | 4000 | 1.6601 |
| 03:25 ET | 9739 | 1.72 |
| 03:57 ET | 300 | 1.62 |
| 03:59 ET | 1283 | 1.65 |
Sep 3, 2024
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, from 8:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
8:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LAVA Therapeutics NV | 43.4M | -1.8x | --- |
Kezar Life Sciences Inc | 38.6M | -0.4x | --- |
Atara Biotherapeutics Inc | 43.4M | -0.2x | --- |
DURECT Corp | 39.7M | -2.4x | --- |
Kronos Bio Inc | 57.6M | -0.5x | --- |
BioLine RX Ltd | 53.6M | -0.8x | --- |
Company Information
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Contact Information
- Headquarters
- Yalelaan 60UTRECHT, Netherlands 3584 CM
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Kapil Dhingra
- President, Chief Executive Officer, Management Director
- Stephen Hurly
- Chief Financial Officer
- Edward Smith
- Executive Vice President Head of Research and Development
- Paul Parren
- Chief Scientific Officer
- Hans Van Der Vliet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.4M |
|---|---|
Revenue (TTM) | $7.4M |
Shares Outstanding | 26.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.51 |
EPS | $-0.90 |
Book Value | $1.95 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -371.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
